Irregularities in the body's genetic coding to make proteins are linked to cancerous tumors. But most genetic material contains elements whose function isn’t clear.

Could abnormalities in non-coding material also impact a person’s health, or even be linked to cancers as well?

Experts from Newcastle University found the nervous system of people with post-COVID fatigue was underactive in three key areas. Fatigue is one of the most common symptoms of long COVID.

The breakthrough could lead to better treatment and tests to identify the condition and the team are already progressing the work having just started a trial.

Strategies to treat pain without triggering dangerous side effects such as euphoria and addiction have proven elusive. For decades, scientists have attempted to develop drugs that selectively activate one type of opioid receptor to treat pain while not activating another type of opioid receptor linked to addiction. Unfortunately, those compounds can cause a different unwanted effect: hallucinations.

A new Nature Immunology study led by University of Pittsburgh and National Institutes of Health researchers sheds light on how a rare type of helper T cell, called Th9, can drive allergic disease, suggesting new precision medicine approaches to treating allergies in patients with high levels of Th9.

Gene-editing therapy aimed at two targets - HIV-1, the virus that causes AIDS, and CCR5, the co-receptor that helps the virus get into cells - can effectively eliminate HIV infection, new research from the Lewis Katz School of Medicine at Temple University and the University of Nebraska Medical Center (UNMC) shows. The study, published online in the journal The Proceedings of the National Academy of Sciences (PNAS), is the first to combine a dual gene-editing strategy with antiretroviral drugs to cure animals of HIV-1.

A new approach to the genetic engineering of cells promises significant improvements in speed, efficiency, and reduction in cellular toxicity compared to current methods. The approach could also power the development of advanced cell therapies for cancers and other diseases, according to a study from researchers in the Perelman School of Medicine at the University of Pennsylvania.

The University of Cincinnati's Soma Sengupta, MD, PhD, published an article in the Journal of Neuro-Oncology April 25 discussing her journey and approach to practicing integrative neuro-oncology.

Sengupta, associate professor in neurology, director of neuro-oncology clinical trials, associate director of the Brain Tumor Center and a UC Health neuro-oncologist,